Amgen's third-quarter results demonstrated strong sales across key products, leading to raised revenue and EPS guidance for 2014. Positive developments in their pipeline, including multiple successful Phase 3 trials and upcoming product launches, signal robust future growth. With strong financial performance and an optimistic outlook, the stock is likely to rally in the short term.

[2]